Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term leucovorin. Found 12 abstracts

Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016 Jun;5:S84-S86.   PMCID: Editorial
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 2012 Nov;18(21):6023-31.
O'Grady MA, Slater E, Sigurdson ER, Meropol NJ, Weinstein A, Lusch CJ, Sein E, Keeley P, Miller B, Engstrom PF, Cohen SJ. Assessing Compliance with National Comprehensive Cancer Network Guidelines for Elderly Patients with Stage III Colon Cancer: The Fox Chase Cancer Center Partners' Initiative. Clinical Colorectal Cancer. 2011 Jun;10(2):113-6.   PMCID: PMC3388796
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Meropol NJ. Turning point for colorectal cancer clinical trials. JOURNAL OF CLINICAL ONCOLOGY. 2006 Jul;24(21):3322-4.
Damjanov N, Meropol NJ. Oral therapy for colorectal cancer: How to choose. Oncology-New York. 2000 Jun;14(6):799-807.
McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in ovarian cancer. Annals of Oncology. 1999 Jan;10:29-34.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. European Journal of Cancer. 1998 Sep;34(10):1509-13.
Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 1998 Mar;43(3):221-6.
Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR. Phase I dose escalating trial of hyperfractionated pre- operative chemoradiation for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics. 1998 Aug;42(1):43-50.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term leucovorin

leucovorin 5-fluorouracil fluorouracil chemotherapy uracil oxaliplatin trial anti-tumor activity cisplatin infusion fluorouracil tegafur 5-ethynyluracil 776c85 bevacizumab combination colorectal cancer adenocarcinoma adjuvant chemotherapy age modulation phase-ii trial overexpression neurotoxicity colon-cancer capecitabine 2nd-line therapy metastatic colorectal-cancer dose Gynecologic Oncology Group (GOG) protocols microsatellite instability infusion efficacy irradiation recurrent neoplasm recurrence older plasma ftorafur new drugs N-phosphonacetyl-L-aspartate phase-ii-trial colonic neoplasms pre-operative therapy mitomycin-c therapy cetuximab solid prevention prodrug long-term survival p53 UFT antitumor-activity dihydropyrimidine dehydrogenase-activity controlled-trial oral chemotherapy randomized trial doxorubicin platinum-resistant improves survival growth-factor receptor survival biochemical modulation phase-ii tumors fluorouracil plus leucovorin advanced squamous cell carcinoma of the diastereoisomers stage-iii trials prognosis antiangiogenic therapy irinotecan preoperative radiation-therapy colorectal downstaging resectable adenocarcinoma lymph-node micrometastases folinic acid Performance cancer taxanes unresectable liver metastases 1- colorectal-cancer carcinoma recombinant interferon alpha Community oncology rectal cancer ethynyluracil phase-iii trial continuous-infusion 5-fluorouracil thymidine phosphorylase randomized cyclophosphamide Gerontologic oncology Quality oncology-group Oncology regimen rectosigmoid carcinoma platinum plus irinotecan improvement oxaliplatin-based S-1 kras endothelial growth-factor dihydropyrimidine dehydrogenase high-dose colorectal-carcinoma adjuvant NCCN Clinical Practice Guidelines surgery pooled analysis methotrexate vegf-trap Colon cancer k-ras head and neck prostate cancer fluorouracil infusion 1995 lkman j-nature medicine-v1-p27 radiation neoplasm staging quality prednisone (2-tetrahydrofuryl)-5-fluorouracil tumor-development
Last updated on Friday, January 03, 2020